Early Phase 1 Epilepsy Trial, Recruiting NCT05594017 Sponsor: University of Texas Southwestern Medical Center Condition: Epilepsy
Back to Epilepsy

Early Phase 1 Epilepsy Trial, Recruiting

NCT05594017
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 55 years, of any race, ethnicity, or gender
  • People whose treating doctor has already decided, as part of their normal medical care, that they need pre-surgery brain monitoring using internal electrodes and a stay in an Epilepsy Monitoring Unit
  • People who are able to read, understand, and sign a written consent form before the screening process begins
  • People who are in generally good health aside from their epilepsy, based on medical history, physical check-up, lab tests, and a heart trace (ECG)
  • People with a body mass index (a height-to-weight measurement) between 18 and 35

Who may not be able to join:

  • People who have a significant abnormal finding on their physical check-up that could affect safety or interfere with the study results, as determined by the study doctor
  • Women who are pregnant, breastfeeding, or who test positive for pregnancy at screening; also, people who test positive for certain substances (such as cannabis, cocaine, amphetamines, barbiturates, or opiates not explained by their prescribed medicines) at screening
  • People with a history of kidney problems or kidney insufficiency
  • People with unstable or active heart problems
  • People with liver failure
  • People with an enlarged prostate (BPH)
  • People with an autoimmune condition affecting the nerves (autoimmune neuropathy)
  • People with an overactive thyroid that is not currently under control
  • People with a history of dementia
  • People who have previously experienced confusion or delirium after using a scopolamine skin patch
  • People with a history of a specific type of eye pressure condition called narrow-angle glaucoma
  • People with a history of a blocked or non-functioning digestive tract (pyloric obstruction or paralytic ileus)
  • People with a history of myasthenia gravis, a condition causing urinary blockage (obstructive uropathy), or a rare blood disorder called porphyria

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Bradley C Lega, MD, University of Texas Southwestern Medical Center

Phone: 214-648-7816

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
1 August 2019
Est. completion
30 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs); Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs); Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs); Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs); Memory-related changes in brain electrical activity in parti...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov